Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230557 | 0.88 | ATM (0.40) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL1537426 | 0.86 | ATM (0.49) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL73426 | 0.86 | ATM (0.41) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL65272 | 0.84 | ATM (0.46) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL66085 | 0.84 | ATM (0.44) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL229125 | 0.83 | TSHR (0.50) | ATMHCAR2SMN1; SMN2TSHRHPGD | |
| SCHEMBL22367588 | 0.82 | HCAR2 (0.53) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL64811 | 0.82 | ATM (0.46) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL8640131 | 0.81 | ATM (0.44) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL1632990 | 0.81 | ATM (0.44) | ATMHCAR2MAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247590-B2 | Method for preventing polymerization of unsaturated organosilicon compounds | WACKER CHEMIE AG (DE) | 2012-08-21 | — | — | US | disclosed |
| EP-2334690-B1 | METHOD FOR PRODUCING (METH)ACRYLOSILANES | WACKER CHEMIE AG (DE) | 2012-07-25 | — | — | EP | disclosed |
| EP-2300486-B1 | METHOD FOR PREVENTING POLYMERIZATION OF UNSATURATED ORGANOSILICON COMPOUNDS | WACKER CHEMIE AG (DE) | 2012-03-28 | — | — | EP | disclosed |
| US-20110118493-A1 | METHOD FOR PREVENTING POLYMERIZATION OF UNSATURATED ORGANOSILICON COMPOUNDS | WACKER CHEMIE AG (DE) | 2011-05-19 | — | — | US | disclosed |
| US-7619108-B2 | Process for preparing unsaturated organosilicon compounds | WACKER CHEMIE AG (DE) | 2009-11-17 | — | — | US | disclosed |
| EP-1954701-B1 | PROCESS FOR PREPARING UNSATURATED ORGANOSILICON COMPOUNDS | WACKER CHEMIE AG (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080293958-A1 | Process for Preparing Unsaturated Organosilicon Compounds | WACKER CHEMIE AG (DE) | 2008-11-27 | — | — | US | disclosed |
| US-6841694-B2 | Process for stabilizing unsaturated organosilicon compounds | WACKER-CHEMIE GMBH (DE) | 2005-01-11 | — | — | US | disclosed |
| US-6815554-B2 | REACTING A HALOALKYLSILANE WITH A SALT OF AN UNSATURATED CARBOXYLIC ACID IN THE PRESENCE OF A PHASE TRANSFER CATALYST; BONDING AGENTS | WACKER-CHEMIE GMBH (DE) | 2004-11-09 | — | — | US | disclosed |
| EP-1469002-A1 | Method for stabilizing unsaturated organo-silicon compounds | Wacker-Chemie GmbH (DE) | 2004-10-20 | — | — | EP | disclosed |
| US-20040171859-A1 | Process for stabilizing unsaturated organosilicon compounds | WACKER-CHEMIE GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| US-20020151736-A1 | PROCESS FOR PREPARING UNSATURATED ORGANOSILICON COMPOUNDS | WACKER-CHEMIE GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| EP-1249454-A1 | Preparation of unsaturated organo-silicon compounds | Wacker-Chemie GmbH (DE) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171859-A1 | Process for stabilizing unsaturated organosilicon compounds | ELOVL1, ELOVL6, DEGS1 | ATM 3705/4885HCAR2 1784/4885MAPT 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.